CIPLA

Cipla Limited

Branded generics leader in India, with global generics and specialty in the US and Africa

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1325.10
Market cap
1,07,018 Cr
Stock P/E
31.7
P/B
3.11
Dividend yield
1.2%
ROE (FY26)
11.2%
ROCE (FY26)
15.2%
Operating margin (FY26)
16.6%
Debt / equity (FY26)
0.0075
OCF / EBITDA (FY26)
67.0%
OCF / EBITDA (3Y)
67.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Cipla makes and sells prescription medicines, generics and consumer health products, with its biggest business in India and further businesses in North America, Africa, and emerging markets and Europe.

Company snapshot

6thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-09-30 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 96.1% of revenue

SegmentRevenue shareRevenuePBTAssets
New ventures
4.5%
320 Cr24 Cr0 Cr
Pharmaceuticals
96.1%
6,776 Cr1,781 Cr0 Cr

What we see

Positives
  • ✓Debt-to-equity of 0.01x — the company is largely funded by its own money, not borrowed funds.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales6,678 Cr6,604 Cr6,163 Cr6,694 Cr7,051 Cr7,073 Cr6,730 Cr6,957 Cr7,589 Cr7,074 Cr6,541 Cr7,119 Cr
Operating expenses (approx.)4,944 Cr4,856 Cr4,847 Cr4,978 Cr5,165 Cr5,084 Cr5,192 Cr5,179 Cr5,695 Cr5,819 Cr5,586 Cr5,927 Cr
EBITDA1,734 Cr1,748 Cr1,316 Cr1,716 Cr1,886 Cr1,989 Cr1,538 Cr1,778 Cr1,895 Cr1,255 Cr955 Cr1,192 Cr
OPM %26.0%26.5%21.4%25.6%26.7%28.1%22.8%25.6%25.0%17.7%14.6%16.7%
Other income176 Cr185 Cr249 Cr160 Cr191 Cr222 Cr289 Cr259 Cr269 Cr206 Cr148 Cr211 Cr
Interest26 Cr30 Cr18 Cr18 Cr15 Cr15 Cr14 Cr14 Cr13 Cr14 Cr13 Cr17 Cr
Depreciation290 Cr233 Cr288 Cr247 Cr272 Cr280 Cr309 Cr253 Cr297 Cr278 Cr383 Cr304 Cr
Profit before tax1,594 Cr1,474 Cr1,257 Cr1,611 Cr1,788 Cr1,907 Cr1,493 Cr1,769 Cr1,854 Cr893 Cr699 Cr1,080 Cr
Tax %27.5%27.5%25.8%27.0%27.0%17.4%18.7%27.0%27.0%24.5%22.4%27.3%
Net profit1,155 Cr1,068 Cr932 Cr1,175 Cr1,305 Cr1,575 Cr1,214 Cr1,292 Cr1,353 Cr674 Cr543 Cr786 Cr
EPS (₹)₹14.01₹13.08₹11.63₹14.58₹16.13₹19.45₹15.13₹16.07₹16.73₹8.37₹6.87₹9.77

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales14,630 Cr15,219 Cr16,362 Cr17,132 Cr19,160 Cr21,763 Cr22,753 Cr25,774 Cr27,548 Cr28,163 CrSign in free for the trailing twelve months
Operating expenses (approx.)12,154 Cr12,393 Cr13,265 Cr13,926 Cr14,907 Cr17,211 Cr17,726 Cr19,483 Cr20,420 Cr22,280 CrSign in free for the trailing twelve months
EBITDA2,476 Cr2,826 Cr3,097 Cr3,206 Cr4,252 Cr4,553 Cr5,027 Cr6,291 Cr7,128 Cr5,883 CrSign in free for the trailing twelve months
OPM %16.9%18.6%18.9%18.7%22.2%20.9%22.1%24.4%25.9%20.9%Sign in free for the trailing twelve months
Other income229 Cr358 Cr477 Cr344 Cr266 Cr281 Cr475 Cr747 Cr862 Cr882 CrSign in free for the trailing twelve months
Interest159 Cr114 Cr168 Cr197 Cr161 Cr106 Cr110 Cr90 Cr62 Cr54 CrSign in free for the trailing twelve months
Depreciation1,323 Cr1,323 Cr1,326 Cr1,175 Cr1,068 Cr1,052 Cr1,172 Cr1,051 Cr1,107 Cr1,211 CrSign in free for the trailing twelve months
Profit before tax1,215 Cr1,667 Cr2,062 Cr2,131 Cr3,277 Cr3,480 Cr4,036 Cr5,700 Cr6,799 Cr5,216 CrSign in free for the trailing twelve months
Tax %14.8%15.0%27.6%29.6%27.1%26.8%29.8%27.1%22.5%26.0%Sign in free for the trailing twelve months
Net profit1,035 Cr1,417 Cr1,492 Cr1,500 Cr2,389 Cr2,547 Cr2,833 Cr4,154 Cr5,269 Cr3,862 CrSign in free for the trailing twelve months
EPS (₹)₹12.52₹17.53₹18.97₹19.19₹29.82₹31.20₹34.72₹51.05₹65.29₹48.03Sign in free for the trailing twelve months
Dividend payout %————0.0%15.8%14.2%16.5%19.9%33.5%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital161 Cr161 Cr161 Cr161 Cr161 Cr161 Cr161 Cr161 Cr162 Cr162 Cr
Reserves12,383 Cr14,068 Cr14,851 Cr15,602 Cr18,165 Cr20,680 Cr23,246 Cr26,545 Cr31,032 Cr34,270 Cr
Borrowings4,113 Cr4,098 Cr4,316 Cr2,816 Cr1,537 Cr824 Cr803 Cr247 Cr92 Cr258 Cr
Other liabilities3,943 Cr4,181 Cr4,303 Cr4,789 Cr5,029 Cr5,160 Cr4,947 Cr5,668 Cr6,006 Cr7,718 Cr
Total liabilities21,037 Cr22,861 Cr23,963 Cr23,663 Cr25,152 Cr27,101 Cr29,463 Cr32,718 Cr37,387 Cr42,496 Cr
Fixed assets (net)5,009 Cr5,315 Cr5,114 Cr5,128 Cr4,956 Cr5,164 Cr4,991 Cr5,069 Cr5,262 Cr6,040 Cr
CWIP719 Cr512 Cr331 Cr421 Cr571 Cr383 Cr689 Cr864 Cr1,213 Cr1,586 Cr
Investments973 Cr1,259 Cr2,616 Cr1,595 Cr2,832 Cr2,612 Cr3,722 Cr5,563 Cr8,044 Cr8,223 Cr
Loans & advances——6 Cr6 Cr3 Cr4 Cr8 Cr0.24 Cr16 Cr23 Cr
Inventories3,485 Cr4,045 Cr3,965 Cr4,378 Cr4,669 Cr5,350 Cr5,156 Cr5,238 Cr5,642 Cr6,597 Cr
Trade receivables2,563 Cr3,102 Cr4,151 Cr3,891 Cr3,446 Cr3,424 Cr4,057 Cr4,771 Cr5,506 Cr5,620 Cr
Cash & bank610 Cr853 Cr508 Cr742 Cr793 Cr678 Cr628 Cr640 Cr589 Cr1,018 Cr
Other assets7,677 Cr7,773 Cr7,272 Cr7,501 Cr7,882 Cr9,486 Cr10,212 Cr10,573 Cr11,115 Cr13,388 Cr
Total assets21,037 Cr22,861 Cr23,963 Cr23,663 Cr25,152 Cr27,101 Cr29,463 Cr32,718 Cr37,387 Cr42,496 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity2,382 Cr1,463 Cr1,691 Cr3,068 Cr3,755 Cr3,326 Cr3,238 Cr4,134 Cr5,005 Cr3,940 Cr
Cash from investing-1,310 Cr-854 Cr-1,669 Cr104 Cr-2,387 Cr-1,872 Cr-2,389 Cr-2,988 Cr-3,691 Cr-2,326 Cr
Cash from financing-1,326 Cr-385 Cr-349 Cr-2,949 Cr-1,330 Cr-1,600 Cr-958 Cr-1,200 Cr-1,293 Cr-1,234 Cr
Net cash flow-254 Cr223 Cr-326 Cr224 Cr51 Cr-132 Cr-97 Cr-49 Cr30 Cr473 Cr
Free cash flow (OCF − Capex)1,246 Cr647 Cr1,164 Cr2,068 Cr2,936 Cr2,625 Cr2,055 Cr2,785 Cr3,457 Cr861 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %8.0%9.5%11.3%12.3%17.1%16.3%16.9%21.4%21.9%15.2%
ROE %7.8%9.7%10.0%9.6%12.9%11.9%11.8%15.4%16.9%11.2%
Debtor days64749283655765687373
Inventory days297327337365348352340366380411
Days payable134172165190154165162173191201
Cash conversion cycle227230264258259244243261261282
OCF / EBITDA %96.2%51.8%54.6%95.7%88.3%73.1%64.4%65.7%70.2%67.0%
OCF / EBITDA % (3 years)——65.9%68.2%80.7%84.5%74.6%67.4%67.1%67.8%
Debt / equity0.330.290.290.180.080.040.030.00920.00300.0075
Current ratio2.592.823.292.662.872.993.343.704.243.44
Net debt / EBITDA1.41—1.230.650.180.030.03-0.06-0.07-0.13